| GENE
DISCOVERY AND TARGET VALIDATION |
| At
Oxford BioMedica our state-of-the-art gene transfer technology,
particularly LentiVector®,
and our advanced understanding of gene regulation are being
used in two potent approaches to identify genes involved in disease processes: |
- Target
validation via gene transfer
- Focused
target identification (FTI)
TECHNOLOGY |
- Target
validation using proprietary gene transfer technology for
over-expression or ablation of gene function
- Focused
target identification to detect previously undetectable
drug targets in specific, predefined disease pathways
- Reduced
validation requirements and stronger initial patents
APPLICATIONS
Any disease target.
COMMERCIALISATION
STRATEGY
Oxford BioMedica is seeking partners who are in need of specialised
gene-based validation technology or who wish to use more focused
approaches to target identification. |
Website by College Hill - Life Sciences |
|
|
